Intest Res.  2016 Jul;14(3):218-223. 10.5217/ir.2016.14.3.218.

Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries

• Wei SC

• KMID: 2354963
• DOI: http://doi.org/10.5217/ir.2016.14.3.218

Abstract

BACKGROUND/AIMS
The cost of caring for patients with inflammatory bowel disease (IBD) is high. Without government support, the cost burden will unavoidably rest on the patients and their family. However, the government providing full support will place a large financial burden on the health-care systems of a country. The aim of this study is to understand the current status of public medical insurance systems in caring for IBD patients among Asian countries.
METHODS
Questionnaires inquiring about the availability of public health systems; medical, diagnostic, and endoscopy costs; and coverage rate of biologics use were designed and sent to IBD experts in each of the Asian countries studied. The results were summarized according to the feedback from the responders.
RESULTS
The public health insurance coverage rate is high in Taiwan, Japan, South Korea, China, Hong Kong, and Singapore; but low in Malaysia and India. This probably affected the use of expensive medications mostly, such as biologics, as we found that the percentage of Crohn's disease (CD) treated with biologics were as high as 30%-40% in Japan, where the government covers all expenses for IBD patients. In India, the percentage maybe as low as 1% for CD patients, most of whom need to pay for the biologics themselves.
CONCLUSIONS
There were differences in the public health insurance systems among the Asian countries studied. This reportprovidesthe background information to understand the differences in the treatment of IBD patients among Asian countries.

Keyword

Inflammatory bowel diseases; Public health insurance; Asian; Diagnosis; Treatment

MeSH Terms

Asian Continental Ancestry Group*
Biological Products
China
Crohn Disease
Diagnosis
Endoscopy
Hong Kong
Humans
India
Inflammatory Bowel Diseases*
Insurance Coverage
Insurance*
Japan
Korea
Malaysia
Public Health
Singapore
Taiwan
Biological Products

Reference

1. Burisch J, Jess T, Martinato M, Lakatos PL. ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013; 7:322–337. PMID: 23395397.

2. Xu J, Tang M, Shen J. Trends and factors affecting hospitalization costs in patients with inflammatory bowel disease: a twocenter study over the past decade. Gastroenterol Res Pract. 2013; 2013:267630. DOI: 10.1155/2013/267630. PMID: 24307891.

3. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135:1907–1913. PMID: 18854185.

4. Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011; 12:273–283. PMID: 20967482.

5. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006; 131:719–728. PMID: 16952541.

6. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut. 2011; 60:930–936. PMID: 21228429.

7. Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol. 2013; 6:153–160. PMID: 24039442.

8. Wei SC, Lin MH, Tung CC, et al. A nationwide populationbased study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan. BMC Gastroenterol. 2013; 13:166. DOI: 10.1186/1471-230X-13-166. PMID: 24314308.

9. Uno H, Yao T, Matsui T, et al. Mortality and cause of death in Japanese patients with Crohn's disease. Dis Colon Rectum. 2003; 46(10 Suppl):S15–S21. PMID: 14530654.